Navigation Links
Increased Dividends, Clinical Trial Results, Survey Results, and Updated Financial Guidance - Research Report on Aetna, Biogen, Eli Lilly, WellPoint, and Laboratory Corp. of America
Date:12/13/2013

n Idec Inc. (Biogen Idec) and Swedish Orphan Biovitrum AB jointly announced the publication of detailed results from the pivotal Phase 3 study of ALPROLIX, the Companies' investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B. According to the Company, the study of ALPROLIX showed that people with severe hemophilia B safely and effectively prevented or reduced bleeding episodes with prophylactic infusions every one to two weeks. Glenn Pierce, M.D., Ph.D., Senior Vice President of Global Medical Affairs and Chief Medical Officer at Biogen Idec's Hemophilia Therapeutic Area, said, "If approved, long-lasting ALPROLIX therapy will have the potential to change the way hemophilia B is managed and address a critical need for patients." The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/b95b_BIIB

Eli Lilly & Co. Research Report

On December 5, 2013, Eli Lilly & Co. (Eli Lilly) announced that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. The Company informed that though the safety and tolerability of edivoxetine was consistent with previous studies, the efficacy results do not support a regulatory submission for adjunctive treatment in patients with Major Depressive Disorder (MDD). "While disappointing for people suffering from depression, their families and Lilly, negative studies are unfortunately a reality of biopharmaceutical innovation, and are particularly prevalent in the area of neuroscience given th
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
2. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
3. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
4. Refusing Vaccinations Puts Children At Increased Risk For Whooping Cough
5. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
6. Transvaginal Mesh Settlement Funding Amounts Increased At Legal-Bay
7. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
8. Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
9. U.S. Public and Doctors* Misperceptions Revealed in National Survey Demonstrate Urgent Need for Increased Opioid Dependence Awareness
10. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
11. DebMed to Display Clients Increased Hand Hygiene Compliance Rates and Worlds First Monitored Point-of-Care Dispenser at APIC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Lazarus Effect, a medical device company focused ... facilitate removal of blood clots, announced today that ... issued a new patent (U.S. Patent Number 8,795,305) ... TM and ReCover TM devices. ... stent-retriever (stentriever) with an integrated, novel, cover-based protection ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
...  Medtronic, Inc, one of the world,s largest medical device ... U.S. Department of Justice (DOJ), the Office of the ... Services, and four relators in a qui tam suit ... in the U.S., including pacemakers and implantable cardioverter defibrillators ...
... A three-drug combination treatment for the blood cancer multiple myeloma ... patients, according to a multi-center study led by Andrzej ... the multiple myeloma program at the University of Chicago Medical ... of the phase I-II study on Dec. 12, 2011, ...
Cached Medicine Technology:Settlement Announced in Medtronic Qui Tam Case 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 3
(Date:7/24/2014)... for head and neck cancer (HNC). Evidence suggests certain cancers ... of HNC in patients with DM has not been well ... common type of cancer. It accounts for about 6 percent ... cases and 350,000 cancer deaths worldwide each year. , The ... the risk of HNC in patients with DM. The authors ...
(Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
(Date:7/24/2014)... two or more equally positive outcomes experience paradoxical ... activity in different regions of the brain, according ... research scholar at the Princeton Neuroscience Institute at ... people rated the desirability of more than 300 ... at images of paired products with different or ...
(Date:7/24/2014)... Memantine was initially developed by Merz to ... under the brand name Akatinol; it was later licensed to ... in the USA to Forest Labs as Namenda. Lundbeck reported ... In the US, Forest reported Namenda sales of USD 1.5 ... Australia and the European region has increased the competition from ...
(Date:7/24/2014)... at Carnegie Mellon University, working with high-throughput data ... National Laboratory, have devised a computational method to ... breast cells turn malignant and as they respond ... analyzing how genes interact with each other in ... today by the online journal PLOS Computational ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... ... undergoing leg amputation and detect heart disease earlier if diagnosis and treatment ... legs) were given higher priority by the NHS and there was better ... and Wales, the majority of which are caused by PAD, but there ...
... - Breast cancer patients with early stage disease that has ... radiation after mastectomy, because of the low present-day risk of ... could one day change the course of treatment for thousands ... University of Texas M. D. Anderson Cancer. The research, ...
... ... Sayer looked around for a good, reliable manufacturer for her award-winning cloth diapers, she did ... manufacturing facility, she also discovered a great way for her company to support its community ... Calgary, Alberta, Canada (PRWEB) ...
... may be the culprits, researchers suggest, , FRIDAY, March 5 ... red meat is a risk factor for heart disease, but ... meat -- not unprocessed red meat -- that increases the ... "processed meat" refers to any meat preserved by smoking, curing ...
... ... ... , ... , , , , ...
... ... ... ... ...
Cached Medicine News:Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 2Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 3Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 2Health News:Most early-stage breast cancer patients may not need radiation after mastectomy 3Health News:Ecobumz Diapers are Going Green While Investing in its Own Community and Employing Women Looking to Enter or Re-enter the Workplace 2Health News:Processed Meat May Harm the Heart 2Health News:Processed Meat May Harm the Heart 3Health News:Processed Meat May Harm the Heart 4Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 2Health News:Global AIDS Alliance: U.S. Must Meet Its Obligations to Family Planning 3Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 2Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 3
Jewelers Forceps, delicate, straight....
Forceps, pointed, short jaws, suitable for epilation....
Cilia Forceps, slanted jaws, gold plated....
Accurate implant size. Polyoxymethylene (POM)....
Medicine Products: